Trial reportBlood advances2019
Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.
Open access · goldAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients.Contemporary clinical trials · 2022Trial
- Combination ruxolitinib, belumosudil, and axatilimab yields clinically significant symptomatic improvements in treatment-refractory chronic GVHD.Bone marrow transplantation · 2026Article
- Chronic Graft-versus-host Disease, Part 2: Clinical Success and Roadmap to the Future.Transplantation · 2025Review
- Review
- Oral Chronic Graft-Versus-Host Disease: Pathogenesis, Diagnosis, Current Treatment, and Emerging Therapies.International journal of molecular sciences · 2024Review
- Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.Blood advances · 2023Article
- Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers.Frontiers in immunology · 2023Review
- A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.Blood advances · 2022Article
- Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape.Leukemia · 2022Review
- Engineering IL-2 for immunotherapy of autoimmunity and cancer.Nature reviews. Immunology · 2022Review
- Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.Blood advances · 2022Article
- Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease.Bone marrow transplantation · 2022Article
- Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.Frontiers in immunology · 2022Article
- High proportion of terminally differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2021Article
- Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in Sézary syndrome.Oncoimmunology · 2021Article
- Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.Frontiers in immunology · 2021Review
- Low-dose IL-2 induces CD56Clinical and experimental immunology · 2020Article
- Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD).Frontiers in immunology · 2020Review
- Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.Blood advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Roger BelizaireDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Haesook T KimDepartment of Biostatistics and Computational Biology and.
Samuel J PoryandaDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Nikola V MirkovicDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Evelyn HipolitoDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
William J SavageDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Carol G ReynoldsDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Marie J FieldsDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Jennifer WhangboDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Tomohiro KuboDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Sarah NikiforowDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Edwin P AlyeaDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Philippe ArmandDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Corey S CutlerDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Vincent T HoDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Bruce R BlazarMasonic Cancer Center and.
Joseph H AntinDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Jerome RitzDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.ORCID 0000-0001-5526-4669
Robert J SoifferDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
John KorethDivision of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
Harvard University · USBrigham and Women's Hospital · USUniversity of Minnesota · US
Funding
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5MProject 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5MSingle Cell and ImmunogenomicsP01CA229092 · NCI · DANA-FARBER CANCER INST · PI SOIFFER, ROBERT JON · 2019 to 2023
$13.8MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MManipulation of Immune Responsiveness after Hematopoietic Cell TransplantationR01CA183559 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$3.7MReconstitution of Regulatory T Cells After Stem Cell TransplantationR01CA183560 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$2.5MNCI NIH HHS P01 CA142106NCI NIH HHS P01 CA229092NCI NIH HHS R01 CA183559NCI NIH HHS R01 CA183560NHLBI NIH HHS R01 HL118979NIAID NIH HHS P01 AI056299
Abstract
Chronic graft-versus-host disease (cGVHD) affects >50% of hematopoietic stem cell transplant patients. Extracorporeal photopheresis (ECP), an immunomodulatory therapy, provides clinical benefit in steroid-refractory (SR) cGVHD, possibly via regulatory T (T
Indexed as
AdultAgedCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationChronic DiseaseCombined Modality TherapyFemaleGraft vs Host DiseaseHumansInterleukin-2Killer Cells, NaturalMaleMiddle AgedPhotopheresisTime FactorsInterleukin-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.